Pharmacogenetics to Avoid Loss of Hearing (PALOH) trial: a protocol for a prospective observational implementation trial
Richard Body,
Mark A Turner,
William G Newman,
Paul Wilson,
John Henry McDermott,
Gino Miele,
Peter Roberts,
Fiona Ulph,
Iain Bruce,
Rhona MacLeod,
Shaun Ainsworth,
Rachel Mahood,
Duncan Stoddard,
Ajit Mahaveer,
Rachel Corry,
Julia Garlick,
Laura Kemp,
Karen Harvey,
Nicola Booth
Affiliations
Richard Body
Emergency Department, Manchester University NHS Foundation Trust, Manchester, UK
Mark A Turner
Women`s and Children`s Health, University of Liverpool, Liverpool, UK
William G Newman
58 Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
Paul Wilson
Centre for Primary Care and Health Services Research, Division of Population Health, The University of Manchester, Manchester, UK
John Henry McDermott
Manchester Centre for Genomic, Manchester University NHS Foundation Trust, Manchester, UK
Gino Miele
3 Epistem Ltd, Manchester, UK
Peter Roberts
Market Access & Reimbursement Solutions, Manchester, UK
Fiona Ulph
Division of Psychology and Mental Health, The University of Manchester, Manchester, UK
Iain Bruce
Paediatric ENT Department, Manchester University Hospitals NHS Foundation Trust, Manchester, UK
Rhona MacLeod
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Shaun Ainsworth
Genedrive plc, Manchester, UK
Rachel Mahood
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Duncan Stoddard
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Ajit Mahaveer
1Manchester University NHS Trust Foundation
Rachel Corry
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Julia Garlick
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
Laura Kemp
Genedrive plc, Manchester, UK
Karen Harvey
Neonatal Intensive Care Unit, Liverpool Womens Hospital NHS Foundation Trust, Liverpool, UK
Introduction In conjunction with a beta-lactam, aminoglycosides are the first-choice antibiotic for empirical treatment of sepsis in the neonatal period. The m.1555A>G variant predisposes to ototoxicity after aminoglycoside administration and has a prevalence of 1 in 500. Current genetic testing can take over 24 hours, an unacceptable delay in the acute setting. This prospective-observational trial will implement a rapid point of care test (POCT), facilitating tailored antibiotic prescribing to avoid hearing loss.Methods and analysis The genedrive POCT can detect the m.1555A>G variant in 26 min from buccal swab. This system will be integrated into the clinical pathways at two large UK neonatal centres over a minimum 6-month period. The primary outcome is the number of neonates successfully tested for the variant out of all babies prescribed antibiotics. As a secondary outcome, clinical timings will be compared with data collected prior to implementation, measuring the impact on routine practice.Ethics and dissemination Approval for the trial was granted by the Research Ethics Committee (REC) and Human Research Authority in August 2019. Results will be published in full on completion of the study.Trial registration number ISRCTN13704894.Protocol version V 1.3.